Certolizumab Pegol Efficacy Across Methotrexate Regimens: A Pre‐Specified Analysis of Two Phase III Trials
نویسندگان
چکیده
منابع مشابه
Certolizumab Pegol Efficacy Across Methotrexate Regimens: A Pre‐Specified Analysis of Two Phase III Trials
OBJECTIVE Anti-tumor necrosis factor (anti-TNF) agents are frequently used in combination with methotrexate (MTX) to treat rheumatoid arthritis (RA). We investigated the effect of a background MTX dose, in combination with anti-TNF certolizumab pegol (CZP), on treatment efficacy and safety in RA patients. METHODS A pre-specified subgroup analysis comparing 2 MTX dosage categories (<15 mg/week...
متن کاملCertolizumab pegol in rheumatoid arthritis: a review of Phase III clinical trials and its role in real-life clinical practice
TNF inhibitors (TNFi) have been in use in clinical practice for the treatment of rheumatoid arthritis (RA) since 1998. The first to be licensed was etanercept, a fusion protein consisting of two soluble p75-TNF-receptor domains and the constant fragment of immunoglobulin. Next was the chimeric mouse human antibody infliximab (the first TNFi to be trialed in man) and later the fully human antibo...
متن کاملTwo Dosing Regimens of Certolizumab Pegol in Patients With Active Rheumatoid Arthritis
OBJECTIVE To investigate clinical efficacy and safety of 2 certolizumab pegol (CZP) maintenance dosing regimens plus methotrexate (MTX) in active rheumatoid arthritis (RA) patients achieving the American College of Rheumatology 20% improvement criteria (ACR20) after the CZP 200 mg every 2 weeks open-label run-in period. METHODS DOSEFLEX (dosing flexibility) was a double-blind, placebo-control...
متن کاملEfficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial
BACKGROUND Certolizumab pegol is a PEGylated tumour necrosis factor inhibitor. OBJECTIVE To evaluate the efficacy and safety of certolizumab pegol versus placebo, plus methotrexate (MTX), in patients with active rheumatoid arthritis (RA). METHODS An international, multicentre, phase 3, randomised, double-blind, placebo-controlled study in active adult-onset RA. Patients (n = 619) were rando...
متن کاملLong-Term Maintenance of Certolizumab Pegol Safety and Efficacy, in Combination with Methotrexate and as Monotherapy, in Rheumatoid Arthritis Patients
INTRODUCTION The safety and efficacy of certolizumab pegol (CZP) 400 mg every 4 weeks (Q4W) monotherapy (FAST4WARD/NCT00548834) and in combination with methotrexate (MTX) (014/NCT00544154) in active rheumatoid arthritis (RA) has been published previously. This report outlines final long-term outcomes from the open-label extension (OLE) study (015/NCT00160693), which enrolled patients from these...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Arthritis Care & Research
سال: 2016
ISSN: 2151-464X,2151-4658
DOI: 10.1002/acr.22676